Overview

Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH). Secondary objectives of this study were to evaluate the effects of ambrisentan on other clinical measures of pulmonary arterial hypertension (PAH), long-term treatment success, and survival.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ambrisentan